Glycolipids from Sargassum filipendula , a Natural Alternative for Overcoming ABC Transporter‐Mediated MDR in Cancer
Chemistry & Biodiversity · 2023
DOI: 10.1002/cbdv.202301058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2023. Verfasst von Kelly Muñoz-Losada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Investigación en Compuestos Funcionales, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medell…. Hauptthemen laut MEDLINE: Filipendula, Sargassum, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 64 Literaturangaben. Gefördert von: Universidad de Antioquia, Institute of Chemistry of the University of Antioquia, CODI of the Universidad de Antioquia.
Abstract (Originalsprache)
Chemotherapy is a widely used strategy to treat cancer, a disease that causes millions of deaths each year. However, its efficacy is reduced by the overexpression of ABC transporters, which are proteins that expel the drugs used in chemotherapy and involved in the multidrug resistance (MDR). Glycolipids have been identified as potential inhibitors of ABC transporters. Algae of the genus Sargassum contain high levels of glycolipids, making them a promising therapeutic alternative against the MDR phenotype. Sargassum filipendula glycolipids were obtained by exhaustive maceration with chloroform/methanol, purified by column and thin layer chromatography, and then characterized by FTIR, NMR, and LC‐MS. Cell viability by PI labeling and inhibition of ABC transporters were analyzed by flow cytometry. Assessment of resistance reversal was determined by MTT assay. Ten sulfoquinovosylglycerol‐type compounds were found, and six of them are reported for the first time. In particular, moiety 4 (GL‐4) showed strong and moderate inhibitory activity against ABCC1 and ABCB1 transporters respectively. Treatment of GL‐4 in combination with the antineoplastic drug vincristine sensitized Lucena‐1 cell model to drug and reversed the MDR phenotype. This is the first report of glycolipids isolated from S. filipendula capable of inhibiting ABC transporters and thus overcoming acquired drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grupo de Investigación en Compuestos Funcionales, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, 050010, Colombia.
- Laboratório de Glicobiologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, 21941-902, Brasil.
- Facultad de Ciencias Farmacéuticas y Alimentarias, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, 050010, Colombia.
Förderung
- Universidad de Antioquia
- Institute of Chemistry of the University of Antioquia
- CODI of the Universidad de Antioquia
- Glycobiology Laboratory/IBCCF/UFRJ
- CNPq
- FAPERJ
- Cancer Foundation/Brazil
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Muñoz-Losada, K., Da Costa, K. M., Muñoz-Castiblanco, T., Mejía-Giraldo, J. C., Previato, J. O., Mendonça-Previato, L., & Puertas-Mejía, M. Á. (2023). Glycolipids from Sargassum filipendula , a Natural Alternative for Overcoming ABC Transporter‐Mediated MDR in Cancer. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202301058
Vancouver
Muñoz-Losada K, Da Costa KM, Muñoz-Castiblanco T, Mejía-Giraldo JC, Previato JO, Mendonça-Previato L, et al. Glycolipids from Sargassum filipendula , a Natural Alternative for Overcoming ABC Transporter‐Mediated MDR in Cancer. Chemistry & Biodiversity. 2023. doi:10.1002/cbdv.202301058
BibTeX
@article{MuozLosada2023,
author = {Muñoz-Losada, Kelly and Da Costa, Kelli Monteiro and Muñoz-Castiblanco, Tatiana and Mejía-Giraldo, Juan Camilo and Previato, José Osvaldo and Mendonça-Previato, Lucia and Puertas-Mejía, Miguel Ángel},
title = {Glycolipids from Sargassum filipendula , a Natural Alternative for Overcoming ABC Transporter‐Mediated MDR in Cancer},
journal = {Chemistry & Biodiversity},
year = {2023},
doi = {10.1002/cbdv.202301058}
}
EUVIMED